Clinical trials Brief October 8, 2026, 10:03 AM ET

Shanghai Henlius Biotech registers Phase II/III study of HLX37 in first-line NSCLC

The study, first posted on ClinicalTrials.gov on October 8, 2026, plans to enroll 1438 participants and plans to begin recruiting on November 30, 2026. It compares two doses of HLX37 combined with chemotherapy to pembrolizumab plus chemotherapy in advanced non-small cell lung cancer.

Primary source

ClinicalTrials.gov registry record, October 8, 2026

A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Read the source: A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation